Souhaitez-vous accéder aux communiqués récents ?

Community Partnership Day symbolizes the company's commitment to improving people's lives and serving our local communities  Follow the excitement with #NovartisCPD2017 and #proudmoments2017 via...

Exclusive license for emricasan supports rapidly growing development portfolio in chronic liver diseases, including NASH  Conatus has initiated the Phase IIb ENCORE-LF clinical trial with...

Approval in newly diagnosed FLT3-mutated AML represents the first new treatment in more than 25 years[1],[2]  Rydapt treatment regimen in FLT3-mutated AML demonstrated a significant improvement in...

Now available in the UK, Germany, Italy and Spain, CyPass Micro-Stent is designed to significantly reduce intraocular pressure (IOP) CE indication has been expanded to allow patients to be...

Der Nettoumsatz wächst um 2% (kWk, -1% USD), da die Wachstumstreiber die Einbussen bei Glivec/Gleevec mehr als wettmachen Cosentyx (USD 410 Millionen, +136% kWk) erzielt in allen drei Indikationen...

Chiffre d'affaires net en hausse de 2% (tcc, -1% en USD), car les moteurs de croissance ont plus que compensé l'impact de Gleevec/Glivec Cosentyx (USD 410 millions, +136% tcc):...

Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications Entresto (USD 84...

Novartis and Amgen to co-commercialize AMG 334 (erenumab) in the US; Novartis to gain exclusive rights in Canada Novartis retains commercial rights in rest of world; Amgen retains commercial...

Over 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within...

Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases.  Biosimilar rituximab also recommended to treat blood cancers Comprehensive data...